BNTX - BioNTech SE

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
+4.01 (+3.85%)
At close: 04:00PM EDT
107.75 -0.38 (-0.35%)
After hours: 07:58PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
Previous Close104.12
Bid107.30 x 900
Ask108.20 x 900
Day's Range106.56 - 109.61
52 Week Range100.08 - 188.99
Avg. Volume701,095
Market Cap26.058B
Beta (5Y Monthly)0.21
PE Ratio (TTM)3.98
EPS (TTM)27.20
Earnings DateAug 07, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJun 02, 2022
1y Target Est170.39
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
20% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for BNTX

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Motley Fool

    Why Shares of BioNTech Rose Friday

    Shares of BioNTech (NASDAQ: BNTX) were up as by much as 5.3% on Friday before closing the session up 3.85% after the biotech company announced positive news regarding a clinical trial for its non-small cell lung cancer therapy candidate. The company focuses on immunotherapies to treat cancer, infectious diseases, and other diseases. BioNTech's shares have been sliding because sales of Comirnaty, the COVID-19 vaccine it developed with Pfizer, are falling.

  • Investor's Business Daily

    BioNTech Surges On This Promising Update In Its Bid To Take On Bristol Myers In Lung Cancer Treatment

    BioNTech said Friday almost a third of patients with a hard-to-treat form of lung cancer responded to its treatment — and BNTX stock popped.

  • Reuters

    UPDATE 1-BioNTech's OncoC4 partnership off to good start with mid-stage trial results

    BioNTech said on Friday that a new cancer immunotherapy candidate that it is working on with U.S. partner OncoC4 Inc was shown to shrink tumours in close to 30% of participants in a mid-stage lung cancer trial. The experimental drug, known as gotistobart, was tested on patients with metastatic non-small cell lung cancer which could no longer be helped by a group of so-called checkpoint inhibitor drugs such as Merck & Co's Keytruda. A follow-on trial in the third and last phase of testing typically required for approval would start in the third quarter of this year, BioNTech added in its statement.

  • GlobeNewswire

    BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO

    BNT316/ONC-392 is a next-generation anti-CTLA-4 monoclonal antibody candidate jointly developed by BioNTech and OncoC4 as monotherapy or combination therapy in a range of solid tumor indications, including non-small cell lung cancer (NSCLC)Interim data of BNT316/ONC-392 from the ongoing Phase 1/2 trial to be presented at this year’s ASCO Annual Meeting demonstrate encouraging signs of clinical anti-tumor activity and a manageable safety profile in patients with metastatic, PD-(L)1-resistant NSCL

  • The Wall Street Journal

    Heard on the Street: Investors Are Too Bearish on Vaccine-Makers

    OVER $300 BILLION That's how much has been wiped off the combined market value of [Moderna](, [Pfizer]( and [BioNTech](https://www.

  • The Wall Street Journal

    Vaccine Fatigue Can Give Your Portfolio a Booster

    Moderna Pfizer and its partner BioNTech are among the biggest losers in the healthcare sector this year, dropping more than 25% each. The declines have been driven by a sense that, as the Covid-19 emergency enters the rearview mirror, demand for boosters will continue to wane. Just last week, the European Commission cut the number of vaccines it is purchasing from Pfizer and BioNTech.

  • Zacks

    EMA Panel Endorses Novavax's (NVAX) COVID Jab for Full Approval

    Novavax's (NVAX) protein-based COVID-19 vaccine gets recommendation for full marketing authorization in COVID-19 patients from European Medicines Agency.

  • The Wall Street Journal

    Next Covid Boosters to Target New Strain

    Health authorities and vaccine makers are moving toward targeting the next shot on a form of the XBB strain that is now circulating widely in the U.S.

  • Benzinga

    Amended European Deal For BioNTech-Pfizer's Covid-19 Vaccines Allows Reduced Purchases

    The European Commission (EC) had agreed with BioNTech SE (NASDAQ: BNTX) and Pfizer Inc (NYSE: PFE) on adapting the existing contract on vaccines against Covid-19, including a reduction in the quantity of doses purchased by EU countries under the contract and pushing the delivery deadline to 2026. "The amendment to the existing vaccines supply contract takes into account the improved epidemiological situation while continuing to ensure access to the latest available version of the vaccine should

  • Financial Times

    Brussels and Pfizer agree deal to cut supply of Covid vaccines

    Revised contract addresses concerns over costly glut of unwanted shots as public health threat wanes

  • Reuters

    UPDATE 2-EU, Pfizer/BioNTech announce amendment to COVID vaccine contract

    The European Union and drugmakers Pfizer and BioNTech said on Friday they had reached a deal to amend a COVID-19 vaccine contract, cutting the number the EU must buy and pushing the delivery deadline to 2026. The agreement, first reported by Reuters earlier on Friday, comes after months of talks and amid pressure on Brussels from EU governments to secure a change to the contract because of a global glut of COVID-19 vaccine doses and low demand for boosters. The amended contract matches "evolving needs", said EU Health Commissioner Stella Kyriakides in a statement.

  • Benzinga

    BioNTech's Ready-to-Use Single Dose Vaccine, the Perfect Counterattack to China's Rising XBB1.5 Cases

    In an annual general meeting, BioNTech SE's (NASDAQ: BNTX) CEO and co-founder Ugur Sahin told shareholders the company is working on COVID-19 vaccines targeting XBB.1.5 strains in line with recommendations by the World Health Organization. Last week, an advisory group for the World Health Organization said the current crop of shots should be updated to target the currently dominant XBB strains for the upcoming winter season. The company said it was on track to introduce a COVID-19 shot by the ea

  • Reuters

    BioNTech is proceeding with COVID-shot in line with WHO guidance

    Germany's BioNTech said it was on track to introduce a COVID-19 shot by the early fall in the northern hemisphere that is adapted to currently dominant virus variants in line with recommendations by the World Health Organization. BioNTech was targeting regulatory approval by the end of the summer to allow for a seasonal vaccination campaign to start in early autumn, CEO and co-founder Ugur Sahin told shareholders at the biotech firm's annual general meeting on Thursday. BioNTech is collaborating on the vaccine with Pfizer in markets outside of greater China.

  • Motley Fool

    2 Undervalued Stocks to Buy for Potentially Massive Gains in the Next 10 Years

    One of the best investment strategies is to buy shares of companies that are presently beaten down by the market, but in whose businesses you have full confidence for growth over the long term. Then, as the market bids up their valuation over time, you'll get the benefit of both the company's actual growth as well as its strengthening reputation among other investors. Two stocks the market is ignoring today, but could likely become excellent investments in the next decade, are in the biotechnology space.

  • Reuters

    CureVac files expanded patent lawsuit against Pfizer/BioNTech over mRNA technology

    The company said it filed a counterclaim alleging that Pfizer and its German partner BioNTech infringed on nine of its patents, broader than its original claim of three patents. In July 2022, CureVac had filed a patent lawsuit against BioNTech over the use of mRNA technology in the companies' COVID-19 vaccine. The transfer of the trial to the Eastern District of Virginia from the Federal District Court of Massachusetts is expected to accelerate progress of the case and allow for a likely 2024 trial date, CureVac said on Friday.

  • Reuters

    UPDATE 1-CureVac files expanded patent lawsuit against Pfizer/BioNTech over mRNA technology

    CureVac NV said on Friday it had filed an expanded patent infringement claim against Pfizer Inc and BioNTech over the use of mRNA technology and that a U.S. court had granted its request to transfer the trial. The company said it filed a counterclaim alleging that Pfizer and its German partner BioNTech infringed on nine of its patents, broader than its original claim of three patents. In July 2022, CureVac had filed a patent lawsuit against BioNTech over the use of mRNA technology in the companies' COVID-19 vaccine.

  • InvestorPlace

    7 Safe Stocks to Buy for an Economic Downward Spiral

    For those that want to stay in the market during these ambiguous times, investors should consider safe stocks to buy. Basically, as Wall Street rotates away from risk-on assets, companies exclusively tied to growth and little else run the risk of suffering sharp losses. At the same time, when discussing safe stocks to buy, you often hear a list of the usual suspects. And while those ideas have considerable merit, I decided to change things up with less-orthodox ideas for portfolio protection. Ea

  • Benzinga

    Why Matinas BioPharma Stock Is Sinking Today

    BioNTech SE (NASDAQ: BNTX) and Matinas BioPharma Holdings Inc (NYSE: MTNB) have ended an mRNA-based collaboration. Matinas reported the update in its Q1 earnings release. The exclusive collaboration with BioNTech was announced just a year ago, with BioNTech paying Matinas an undisclosed amount in exchange for access to Matinas' lipid nanocrystal (LNC) drug delivery platform. BioNTech had also paid Matinas an upfront access fee. The company said that in May 2023, the initial in vivo study of an o

  • Investopedia

    Top Healthcare Stocks for May 2023

    Top healthcare stocks include Azenta Inc. for best value, ShockWave Medical for fastest growth, and Viking Therapeutics for most momentum.

  • Thomson Reuters StreetEvents

    Q1 2023 Matinas BioPharma Holdings Inc Earnings Call

    Q1 2023 Matinas BioPharma Holdings Inc Earnings Call

  • Reuters

    UPDATE 1-BioNTech, Roche's experimental pancreatic cancer treatment wins Nature plaudit

    Scientific journal Nature on Wednesday said a personalised treatment based on messenger RNA by BioNTech potentially bodes well for the future of fighting an extremely aggressive form of cancer after the regimen was shown to trigger a promising immune reaction in some pancreatic cancer patients. Results of a trial in the first phase of testing on humans showed that half of the 16 trial participants, who had undergone surgery to remove their tumour, had developed T cells that can potentially recognise cancerous cells and stop them from re-emerging, Nature said in a paper on Wednesday. The readout, which was reported first by BioNTech in June of last year, is adding to evidence that the technology behind COVID-19 vaccines has potential in oncology.

  • Thomson Reuters StreetEvents

    Q1 2023 BioNTech SE Earnings Call

    Q1 2023 BioNTech SE Earnings Call

  • Investor's Business Daily

    BioNTech Trounces First-Quarter Profit Views, But Covid Declines Will Continue

    BioNTech crushed Wall Street's profit views Monday, but shares dipped at the close amid expectations for more drops in Covid vaccine sales.

  • Motley Fool

    BioNTech Se (BNTX) Q1 2023 Earnings Call Transcript

    Image source: The Motley Fool. BioNTech Se (NASDAQ: BNTX)Q1 2023 Earnings CallMay 08, 2023, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorWelcome to the BioNTech first quarter 2023 update call.